Down-regulation of myopodin expression reduces invasion and motility of PC-3 prostate cancer cells

International Journal of Oncology

Volumn 34, Issue 5, 2009, Pages 1403-1409

  De Ganck, Arianne ^a   De Corte, Veerle ^a   Bruyneel, Erik ^b   Bracke, Marc ^b   Vandekerckhove, Joel ^a   Gettemans, Jan ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cancer; Invasion; Myopodin; RNA interference

Indexed keywords

COLLAGEN TYPE 1; MATRIGEL; MYOPODIN; SMALL INTERFERING RNA; SYNAPTOPODIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INVASION; CELL CONTACT; CELL MOTILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RNA INTERFERENCE;

CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICROFILAMENT PROTEINS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

EID: 67649421072     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000268     Document Type: Article

References (47)

1. Kassis J, Laufffenburger DA, Turner T and Wells A: Tumor invasion as dysregulated cell motility. Semin Cancer Biol 11: 105-117, 2001.
2. Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marra MA, Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, Kinzler KW, Strausberg RL and Riggins GJ: A public database for gene expression in human cancers. Cancer Res 59: 5403-5407, 1999.
3. Van Ginkel PR, Gee RL, Walker TM, Hu DN, Heizmann CW and Polans AS: The identification and differential expression of calcium-binding proteins associated with ocular melanoma. Biochim Biophys Acta 1448: 290-297, 1998.
4. Thompson CC, Ashcroft FJ, Patel S, Saraga G, Vimalachandran D, Prime W, Campbell F, Dodson A, Jenkins RE, Lemoine NR, Crnogorac-Jurcevic T, Yin HL and Costello E: Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 56: 95-106, 2007.
5. Nomura H, Uzawa K, Ishigami T, Kouzu Y, Koike H, Ogawara K, Siiba M, Bukawa H, Yokoe H, Kubosawa H and Tanzawa H: Clinical significance of gelsolin-like actin-capping protein expression in oral carcinogenesis: an immunohistochemical study of premalignant and malignant lesions of the oral cavity. BMC Cancer 8: 39, 2008.
6. Janke J, Schluter K, Jandrig B, Theile M, Kolble K, Arnold W, Grinstein E, Schwartz A, Estevez-Schwarz L, Schlag PM, Jockusch BM and Scherneck S: Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J Exp Med 191: 1675-1686, 2000.
7. Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, Molina H, Jensen ON, Hruban RH, Goggins MG, Maitra A and Pandey A: Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5: 157-171, 2006.
8. Wu N, Zhang W, Yang Y, Liang YL, Wang LY, Jin JW, Cai XM and Zha XL: Profilin 1 obtained by proteomic analysis in alltrans retinoic acid-treated hepatocarcinoma cell lines is involved in inhibition of cell proliferation and migration. Proteomics 6: 6095-6106, 2006.
9. Goswami S, Wang W, Wyckoff JB and Condeelis JS: Breast cancer cells isolated by chemotaxis from primary tumors show increased survival and resistance to chemotherapy. Cancer Res 64: 7664-7667, 2004.
10. Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E, Singer RH, Segall JE and Condeelis JS: Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 64: 8585-8594, 2004.
11. Weins A, Schwarz K, Faul C, Barisoni L, Linke WA and Mundel P: Differentiation- and stress-dependent nuclear cytoplasmic redistribution of myopodin, a novel actin-bundling protein. J Cell Biol 155: 393-404, 2001.
12. De Ganck A, Hubert T, van Impe K, Geelen D, Vandekerckhove J, De Corte V and Gettemans J: A monopartite nuclear localization sequence regulates nuclear targeting of the actin binding protein myopodin. FEBS Lett 579: 6673-6680, 2005.
13. De Ganck A, De Corte V, Staes A, Gevaert K, Vandekerckhove J and Gettemans J: Multiple isoforms of the tumor suppressor myopodin are simultaneously transcribed in cancer cells. Biochem Biophys Res Commun 370: 269-273, 2008.
14. Lin F, Yu YP, Woods J, Cieply K, Gooding B, Finkelstein P, Dhir R, Krill D, Becich MJ, Michalopoulos G, Finkelstein S and Luo JH: Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers. Am J Pathol 159: 1603-1612, 2001.
15. Sanchez-Carbayo M, Schwarz K, Charytonowicz E, Cordon-Cardo C and Mundel P: Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome. Oncogene 22: 5298-5305, 2003.
16. Jing L, Liu L, Yu YP, Dhir R, Acquafondada M, Landsittel D, Cieply K, Wells A and Luo JH: Expression of myopodin induces suppression of tumor growth and metastasis. Am J Pathol 164: 1799-1806, 2004.
17. Van Impe K, De Corte V, Eichinger L, Bruyneel E, Mareel M, Vandekerckhove J and Gettemans J: The nucleo-cytoplasmic actin-binding protein CapG lacks a nuclear export sequence present in structurally related proteins. J Biol Chem 278: 17945-17952, 2003.
18. De Corte V, Bruyneel E, Boucherie C, Mareel M, Vandekerckhove J and Gettemans J: Gelsolin-induced epithelial cell invasion is dependent on Ras-Rac signaling. EMBO J 21: 6781-6790, 2002.
19. Tanaka M, Sazawa A, Shinohara N, Kobayashi Y, Fujioka Y, Koyanagi T and Kuzumaki N: Gelsolin gene therapy by retrovirus producer cells for human bladder cancer in nude mice. Cancer Gene Ther 6: 482-487, 1999.
20. Watari A, Takaki K, Higashiyama S, Li Y, Satomi Y, Takao T, Tanemura A, Yamaguchi Y, Katayama I, Shimakage M, Miyashiro I, Takami K, Kodama K and Yutsudo M: Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG. Oncogene 25: 7373-7380, 2006.
21. Ding SJ, Li Y, Shao XX, Zhou H, Zeng R, Tang ZY and Xia QC: Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics 4: 982-994, 2004.
22. Lee YJ, Mazzatti DJ, Yun Z and Keng PC: Inhibition of invasiveness of human lung cancer cell line H1299 by overexpression of cofilin. Cell Biol Int 29: 877-883, 2005.
23. Turhani D, Krapfenbauer K, Thurnher D, Langen H and Fountoulakis M: Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis 27: 1417-1423, 2006.
24. Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ and Banks RE: Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 3: 1620-1632, 2003.
25. Hara T, Honda K, Shitashige M, Ono M, Matsuyama H, Naito K, Hirohashi S and Yamada T: Mass spectrometry analysis of the native protein complex containing actinin-4 in prostate cancer cells. Mol Cell Proteomics 6: 479-491, 2007.
26. Honda K, Yamada T, Endo R, Ino Y, Gotoh M, Tsuda H, Yamada Y, Chiba H and Hirohashi S: Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol 140: 1383-1393, 1998.
27. Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F, Ino Y, Ono M and Hirohashi S: Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 128: 51-62, 2005.
28. Pille JY, Denoyelle C, Varet J, Bertrand JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C, Soria C and Li H: Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 11: 267-274, 2005.
29. Bracke ME, Boterberg T, Bruyneel EA and Mareel MM: Collagen invasion assay. In: Metastasis Research Protocols. Brooks SA and Schumacher U (eds). Humana Press, Totowa, 58, pp81-89, 2001.
30. Boterberg T, Bracke ME, Bruyneel EA and Mareel MM: Cell aggregation assays. In: Metastasis Research Protocols. Brooks SA and Schumacher U (eds). Humana Press, Totowa, 58, pp33-45, 2001.
31. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
32. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Biotechnology 24: 145-149, 1979.
33. Terranova VP, Hujanen ES, Loeb DM, Martin GR, Thornburg L and Glushko V: Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells. Proc Natl Acad Sci USA 83: 465-469, 1986.
34. Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T and Konishi I: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 83: 861-870, 2003.
35. Ridley AJ: Rho proteins and cancer. Breast Cancer Res Treat 84: 13-19, 2004.
36. Bracke ME, Charlier C, Bruyneel EA, Labit C, Mareel MM and Castronovo V: Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/ 6 cells and suppresses their invasive phenotype. Cancer Res 54: 4607-4609, 1994.
37. De Corte V, van Impe K, Bruyneel E, Boucherie C, Mareel M, Vandekerckhove J and Gettemans J: Increased importin-beta-dependent nuclear import of the actin modulating protein CapG promotes cell invasion. J Cell Sci 117: 5283-5292, 2004.
38. Van den Abbeele A, De Corte V, van Impe K, Bruyneel E, Boucherie C, Bracke M, Vandekerckhove J and Gettemans J: Down-regulation of gelsolin family proteins counteracts cancer cell invasion in vitro. Cancer Lett 255: 57-70, 2007.
39. Yu YP, Tseng GC and Luo JH: Inactivation of myopodin expression associated with prostate cancer relapse. Urology 68: 578-582, 2006.
40. Yu YP and Luo JH: Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. Cancer Res 66: 7414-7419, 2006.
41. Gettemans J, van Impe K, Delanote V, Hubert T, Vandekerckhove J and De Corte V: Nuclear actin-binding proteins as modulators of gene transcription. Traffic 6: 847-857, 2005.
42. Heery DM, Kalkhoven E, Hoare S and Parker MG: A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387: 733-736, 1997.
43. Iyer AK, Zhang YH and McCabe ER: LXXLL motifs and AF-2 domain mediate SHP (NR0B2) homodimerization and DAX1 (NR0B1)-DAX1A heterodimerization. Mol Genet Metab 92: 151-159, 2007.
44. Savkur RS and Burris TP: The coactivator LXXLL nuclear receptor recognition motif. J Pept Res 63: 207-212, 2004.
45. Samstag Y, Dreizler EM, Ambach A, Sczakiel G and Meuer SC: Inhibition of constitutive serine phosphatase activity in T lymphoma cells results in phosphorylation of pp19/cofilin and induces apoptosis. J Immunol 156: 4167-4173, 1996.
46. Yamamoto S, Tsuda H, Honda K, Kita T, Takano M, Tamai S, Inazawa J, Yamada T and Matsubara O: Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. Mod Pathol 20: 1278-1285, 2007.
47. Shieh DB, Godleski J, Herndon JE, Azuma T, Mercer H, Sugarbaker DJ and Kwiatkowski DJ: Cell motility as a prognostic factor in Stage I non-small cell lung carcinoma: the role of gelsolin expression. Cancer 85: 47-57, 1999.